Small Molecule Drug Discovery Through Deep Learning:Progress, Challenges, and Opportunities

• URL: http://arxiv.org/abs/2502.08975v1
• Date: Thu, 13 Feb 2025 05:24:52 GMT
• Title: Small Molecule Drug Discovery Through Deep Learning:Progress, Challenges, and Opportunities
• Authors: Kun Li, Yida Xiong, Hongzhi Zhang, Xiantao Cai, Bo Du, Wenbin Hu,
• Abstract summary: With the rapid development of deep learning (DL) techniques, DL-based small molecule drug discovery methods have achieved excellent performance.<n>This paper systematically summarize and generalize the recent key tasks and representative techniques in DL-based small molecule drug discovery.
• Score: 34.72068278499029
• License: http://creativecommons.org/licenses/by-nc-nd/4.0/
• Abstract: Due to their excellent drug-like and pharmacokinetic properties, small molecule drugs are widely used to treat various diseases, making them a critical component of drug discovery. In recent years, with the rapid development of deep learning (DL) techniques, DL-based small molecule drug discovery methods have achieved excellent performance in prediction accuracy, speed, and complex molecular relationship modeling compared to traditional machine learning approaches. These advancements enhance drug screening efficiency and optimization, and they provide more precise and effective solutions for various drug discovery tasks. Contributing to this field's development, this paper aims to systematically summarize and generalize the recent key tasks and representative techniques in DL-based small molecule drug discovery in recent years. Specifically, we provide an overview of the major tasks in small molecule drug discovery and their interrelationships. Next, we analyze the six core tasks, summarizing the related methods, commonly used datasets, and technological development trends. Finally, we discuss key challenges, such as interpretability and out-of-distribution generalization, and offer our insights into future research directions for DL-assisted small molecule drug discovery.

Related papers

• PharmAgents: Building a Virtual Pharma with Large Language Model Agents [19.589707628042422]
  We introduce PharmAgents, a virtual pharmaceutical ecosystem driven by multi-agent collaboration. The system integrates explainable, LLM-driven agents equipped with specialized machine learning models and computational tools. It identifies potential therapeutic targets, discovers promising lead compounds, enhances binding affinity and key molecular properties, and performs in silico analyses of toxicity and synthetic feasibility.
  arXiv  Detail & Related papers  (2025-03-28T06:02:53Z)
• Drug-Target Interaction/Affinity Prediction: Deep Learning Models and Advances Review [4.364576564103288]
  Deep learning models have been presented to overcome the challenges of interaction prediction. A total of 180 prediction methods for drug-target interactions were analyzed.
  arXiv  Detail & Related papers  (2025-02-21T10:00:43Z)
• Diffusion Models for Molecules: A Survey of Methods and Tasks [56.44565051667812]
  Generative tasks about molecules are crucial for drug discovery and material design.<n>Diffusion models have emerged as an impressive class of deep generative models.<n>This paper conducts a comprehensive survey of diffusion model-based molecular generative methods.
  arXiv  Detail & Related papers  (2025-02-13T17:22:50Z)
• Large Language Models in Drug Discovery and Development: From Disease Mechanisms to Clinical Trials [49.19897427783105]
  The integration of Large Language Models (LLMs) into the drug discovery and development field marks a significant paradigm shift. We investigate how these advanced computational models can uncover target-disease linkage, interpret complex biomedical data, enhance drug molecule design, predict drug efficacy and safety profiles, and facilitate clinical trial processes.
  arXiv  Detail & Related papers  (2024-09-06T02:03:38Z)
• Hybrid quantum cycle generative adversarial network for small molecule generation [0.0]
  This work introduces several new generative adversarial network models based on engineering integration of parametrized quantum circuits into known molecular generative adversarial networks. The introduced machine learning models incorporate a new multi- parameter reward function grounded in reinforcement learning principles.
  arXiv  Detail & Related papers  (2023-12-28T14:10:26Z)
• CardiGraphormer: Unveiling the Power of Self-Supervised Learning in Revolutionizing Drug Discovery [0.32634122554914]
  CardiGraphormer is a novel combination of Graphormer and Cardinality Preserving Attention. SSL performs to learn potent molecular representations and employs GNNs to extract molecular fingerprints. CardiGraphormer's potential applications in drug discovery and drug interactions are vast.
  arXiv  Detail & Related papers  (2023-07-03T08:58:32Z)
• Deep Learning Methods for Small Molecule Drug Discovery: A Survey [6.61864409597243]
  We review various applications of deep learning in drug discovery. These include molecule generation, molecular property prediction, retrosynthesis prediction, and reaction prediction. We conclude by identifying remaining challenges and discussing the future trend for deep learning methods in drug discovery.
  arXiv  Detail & Related papers  (2023-03-01T08:16:38Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Molecule Generation for Drug Design: a Graph Learning Perspective [49.8071944694075]
  Machine learning, particularly graph learning, is gaining increasing recognition for its transformative impact across various fields. One such promising application is in the realm of molecule design and discovery, notably within the pharmaceutical industry. Our survey offers a comprehensive overview of state-of-the-art methods in molecule design, particularly focusing on emphde novo drug design, which incorporates (deep) graph learning techniques.
  arXiv  Detail & Related papers  (2022-02-18T14:26:23Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.